Cargando…

Current Efavirenz (EFV) or Ritonavir-Boosted Lopinavir (LPV/r) Use Correlates with Elevate Markers of Atherosclerosis in HIV-Infected Subjects in Addis Ababa, Ethiopia

BACKGROUND: HIV patients on antiretroviral therapy have shown elevated incidence of dyslipidemia, lipodystrophy, and cardiovascular disease (CVD). Most studies, however, focus on cohorts from developed countries, with less data available for these co-morbidities in Ethiopia and sub-Saharan Africa. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gleason, Rudolph L., Caulk, Alexander W., Seifu, Daniel, Parker, Ivana, Vidakovic, Brani, Getenet, Helena, Assefa, Getachew, Amogne, Wondwossen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411122/ https://www.ncbi.nlm.nih.gov/pubmed/25915208 http://dx.doi.org/10.1371/journal.pone.0117125

Ejemplares similares

Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
por: Muche Belete, Abebe, et al.
Publicado: (2021)

Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r)
por: Tookey, Pat, et al.
Publicado: (2014)

Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
por: Marima, Rahaba, et al.
Publicado: (2020)

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
por: Maroldo, L, et al.
Publicado: (2010)

Herbal Medicine Use and Determinant Factors Among HIV/AIDS Patients on Antiretroviral Therapy in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia
por: Shiferaw, Abebe, et al.
Publicado: (2020)

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy
por: Martin, Allison, et al.
Publicado: (2013)

Prevalence and correlates of depression and anxiety among patients with HIV on-follow up at Alert Hospital, Addis Ababa, Ethiopia
por: Tesfaw, Getachew, et al.
Publicado: (2016)

Asymptomatic Bacteriuria among Pregnant Women in Addis Ababa, Ethiopia: Prevalence, Causal Agents, and Their Antimicrobial Susceptibility
por: Bizuwork, Ketema, et al.
Publicado: (2021)

HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)
por: Baran, RW, et al.
Publicado: (2010)

Risk perceptions and preventive practices of COVID-19 among healthcare professionals in public hospitals in Addis Ababa, Ethiopia
por: Deressa, Wakgari, et al.
Publicado: (2021)

Availability and use of personal protective equipment and satisfaction of healthcare professionals during COVID-19 pandemic in Addis Ababa, Ethiopia
por: Deressa, Wakgari, et al.
Publicado: (2021)

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens
por: Qaqish, R, et al.
Publicado: (2010)

Maternal Complications and Adverse Pregnancy Outcomes among Pregnant Women who Acquired Asymptomatic Bacteriuria in Addis Ababa, Ethiopia
por: Gebremedhin, Ketema Bizuwork, et al.
Publicado: (2021)

Evolution of Framingham cardiovascular risk score in HIV-infected patients initiating EFV- and LPV/r-based HAART in a Latin American cohort
por: Cecchini, Diego, et al.
Publicado: (2014)

Distribution of virulence genes and phylogenetics of uropathogenic Escherichia coli among urinary tract infection patients in Addis Ababa, Ethiopia
por: Dadi, Belayneh Regasa, et al.
Publicado: (2020)

High Mortality from Blood Stream Infection in Addis Ababa, Ethiopia, Is Due to Antimicrobial Resistance
por: Seboxa, Teshale, et al.
Publicado: (2015)

Oral health knowledge and oral hygiene practice among visually impaired subjects in Addis Ababa, Ethiopia
por: Fantaye, Wondwossen, et al.
Publicado: (2022)

543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults
por: Thompson, Melanie, et al.
Publicado: (2018)

Management of hospital-acquired infections among patients hospitalized at Zewditu memorial hospital, Addis Ababa, Ethiopia: A prospective cross-sectional study
por: Tassew, Segen Gebremeskel, et al.
Publicado: (2020)

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
por: Orkin, C, et al.
Publicado: (2010)

144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohort
por: Wolf, Eva, et al.
Publicado: (2014)

Clinical and Epidemiological Profiles of Patients with End Stage Kidney Disease on Dialysis at Dialysis Centers in Addis Ababa, Ethiopia
por: Seifu, Lissane, et al.
Publicado: (2023)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Anticoagulation Management in Patients Receiving Warfarin at Private Cardiac Centers in Addis Ababa, Ethiopia
por: Getachew, Roza, et al.
Publicado: (2023)

Reduced Effectiveness of Contraceptive Implants for Women Taking the Antiretroviral Efavirenz (EFV): Still Good Enough and for How Long?
por: Shelton, James D
Publicado: (2015)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Wiriyatanakorn, Sirichai, et al.
Publicado: (2019)

Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients
por: Berno, Giulia, et al.
Publicado: (2014)

Brain Magnetic Resonance Imaging Findings in Patients with Developmental Delay in Addis Ababa, Ethiopia
por: Balcha, Tewodros Endale, et al.
Publicado: (2022)

Determinants of stock-outs of first line anti-tuberculosis drugs: the case of public health facilities of Addis Ababa city administration health bureau, Addis Ababa, Ethiopia
por: Sintayehu, Kassech, et al.
Publicado: (2022)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

Determinants of multidrug-resistant tuberculosis in Addis Ababa, Ethiopia
por: Assefa, Demelash, et al.
Publicado: (2017)

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
por: Lazzarin, A, et al.
Publicado: (2010)

Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China
por: Su, Bin, et al.
Publicado: (2019)

A magnifying glass onto renal function and serum lipid evolutions after tenofovir (TDF) and emtricitabine (FTC) in combination with atazanavir/ritonavir (ATV/r) versus efavirenz (EFV) as first-line HAART (the INCA trial)
por: Izzo, I, et al.
Publicado: (2010)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_911u1d6s5536u9e86drscp1uav